Overview of the extranigral aspects of Parkinson disease.
Identifieur interne : 001E03 ( Main/Exploration ); précédent : 001E02; suivant : 001E04Overview of the extranigral aspects of Parkinson disease.
Auteurs : Shen-Yang Lim [Canada] ; Susan H. Fox ; Anthony E. LangSource :
- Archives of neurology [ 1538-3687 ] ; 2009.
English descriptors
- KwdEn :
- Antiparkinson Agents (pharmacology), Antiparkinson Agents (therapeutic use), Autonomic Nervous System Diseases (etiology), Autonomic Nervous System Diseases (pathology), Autonomic Nervous System Diseases (physiopathology), Brain (pathology), Brain (physiopathology), Disease Progression, Humans, Lewy Bodies (metabolism), Lewy Bodies (pathology), Nerve Degeneration (pathology), Nerve Degeneration (physiopathology), Neural Pathways (pathology), Neural Pathways (physiopathology), Neurons (metabolism), Neurons (pathology), Neurotransmitter Agents (metabolism), Parkinson Disease (complications), Parkinson Disease (pathology), Parkinson Disease (physiopathology).
- MESH :
- chemical , metabolism : Neurotransmitter Agents.
- chemical , pharmacology : Antiparkinson Agents.
- chemical , therapeutic use : Antiparkinson Agents.
- complications : Parkinson Disease.
- etiology : Autonomic Nervous System Diseases.
- metabolism : Lewy Bodies, Neurons.
- pathology : Autonomic Nervous System Diseases, Brain, Lewy Bodies, Nerve Degeneration, Neural Pathways, Neurons, Parkinson Disease.
- physiopathology : Autonomic Nervous System Diseases, Brain, Nerve Degeneration, Neural Pathways, Parkinson Disease.
- Disease Progression, Humans.
Abstract
In recent years, there has been increasing recognition of the features of Parkinson disease that are not related to nigrostriatal dopamine deficiency. This review addresses selected clinical, anatomic, pathologic, and biochemical correlates of the early premotor symptoms of Parkinson disease, later nonmotor fluctuations, and advanced dopa-unresponsive motor and nonmotor features. The recognition of early features that predate classic motor symptoms will be important as effective neuroprotective therapy becomes available. Later-stage features often contribute markedly to disability and impaired quality of life and, therefore, represent an important future therapeutic challenge.
DOI: 10.1001/archneurol.2008.561
PubMed: 19204152
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000E99
- to stream PubMed, to step Curation: 000E99
- to stream PubMed, to step Checkpoint: 000E99
- to stream Ncbi, to step Merge: 000A28
- to stream Ncbi, to step Curation: 000A28
- to stream Ncbi, to step Checkpoint: 000A28
- to stream Main, to step Merge: 001F51
- to stream Main, to step Curation: 001E03
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Overview of the extranigral aspects of Parkinson disease.</title><author><name sortKey="Lim, Shen Yang" sort="Lim, Shen Yang" uniqKey="Lim S" first="Shen-Yang" last="Lim">Shen-Yang Lim</name><affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Centre, Toronto Western Hospital, 399 Bathurst St, Toronto, Ontario M5T 2S8, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Movement Disorders Centre, Toronto Western Hospital, 399 Bathurst St, Toronto, Ontario M5T 2S8</wicri:regionArea><wicri:noRegion>Ontario M5T 2S8</wicri:noRegion></affiliation></author><author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H" last="Fox">Susan H. Fox</name></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19204152</idno><idno type="pmid">19204152</idno><idno type="doi">10.1001/archneurol.2008.561</idno><idno type="wicri:Area/PubMed/Corpus">000E99</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E99</idno><idno type="wicri:Area/PubMed/Curation">000E99</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000E99</idno><idno type="wicri:Area/PubMed/Checkpoint">000E99</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000E99</idno><idno type="wicri:Area/Ncbi/Merge">000A28</idno><idno type="wicri:Area/Ncbi/Curation">000A28</idno><idno type="wicri:Area/Ncbi/Checkpoint">000A28</idno><idno type="wicri:Area/Main/Merge">001F51</idno><idno type="wicri:Area/Main/Curation">001E03</idno><idno type="wicri:Area/Main/Exploration">001E03</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Overview of the extranigral aspects of Parkinson disease.</title><author><name sortKey="Lim, Shen Yang" sort="Lim, Shen Yang" uniqKey="Lim S" first="Shen-Yang" last="Lim">Shen-Yang Lim</name><affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Centre, Toronto Western Hospital, 399 Bathurst St, Toronto, Ontario M5T 2S8, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Movement Disorders Centre, Toronto Western Hospital, 399 Bathurst St, Toronto, Ontario M5T 2S8</wicri:regionArea><wicri:noRegion>Ontario M5T 2S8</wicri:noRegion></affiliation></author><author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H" last="Fox">Susan H. Fox</name></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name></author></analytic><series><title level="j">Archives of neurology</title><idno type="eISSN">1538-3687</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (pharmacology)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Autonomic Nervous System Diseases (etiology)</term><term>Autonomic Nervous System Diseases (pathology)</term><term>Autonomic Nervous System Diseases (physiopathology)</term><term>Brain (pathology)</term><term>Brain (physiopathology)</term><term>Disease Progression</term><term>Humans</term><term>Lewy Bodies (metabolism)</term><term>Lewy Bodies (pathology)</term><term>Nerve Degeneration (pathology)</term><term>Nerve Degeneration (physiopathology)</term><term>Neural Pathways (pathology)</term><term>Neural Pathways (physiopathology)</term><term>Neurons (metabolism)</term><term>Neurons (pathology)</term><term>Neurotransmitter Agents (metabolism)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (pathology)</term><term>Parkinson Disease (physiopathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Neurotransmitter Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Autonomic Nervous System Diseases</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Lewy Bodies</term><term>Neurons</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Autonomic Nervous System Diseases</term><term>Brain</term><term>Lewy Bodies</term><term>Nerve Degeneration</term><term>Neural Pathways</term><term>Neurons</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Autonomic Nervous System Diseases</term><term>Brain</term><term>Nerve Degeneration</term><term>Neural Pathways</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Disease Progression</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In recent years, there has been increasing recognition of the features of Parkinson disease that are not related to nigrostriatal dopamine deficiency. This review addresses selected clinical, anatomic, pathologic, and biochemical correlates of the early premotor symptoms of Parkinson disease, later nonmotor fluctuations, and advanced dopa-unresponsive motor and nonmotor features. The recognition of early features that predate classic motor symptoms will be important as effective neuroprotective therapy becomes available. Later-stage features often contribute markedly to disability and impaired quality of life and, therefore, represent an important future therapeutic challenge.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H" last="Fox">Susan H. Fox</name><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name></noCountry><country name="Canada"><noRegion><name sortKey="Lim, Shen Yang" sort="Lim, Shen Yang" uniqKey="Lim S" first="Shen-Yang" last="Lim">Shen-Yang Lim</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E03 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001E03 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:19204152
|texte= Overview of the extranigral aspects of Parkinson disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:19204152" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |